Katja Weisel is Deputy Director and associate professor of Hematology/Oncology in the Department of Oncology, Hematology and Bone Marrow Transplantation with Department of Pneumonology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Professor Weisel received her medical degree from the Medical School of the University of Ulm, Germany, and did her clinical residency in internal medicine at the University of Tübingen. She did a postdoctoral research fellowship in the laboratory of Developmental Hematopoiesis at the Memorial Sloan-Kettering Cancer Center in New York, USA. She completed her medical fellowship in internal medicine and hematology, oncology at the University of Tübingen.
Professor Weisel led the Tübingen myeloma program from 2006 until she moved to Hamburg in 2019. She now serves as the deputy director of the department, the co-director of the University Cancer Centre Hamburg and is leading the myeloma and lymphoma program. Her myeloma research interests focus on treatment optimisation for high-risk myeloma, renally-impaired myeloma patients, refractory myeloma patients and radiographic methods for disease monitoring of myeloma.
She is a member of the German Speaking Myeloma Multicentre Group (GMMG) steering committee. Professor Weisel is co-investigator in all GMMG trials and is the lead investigator of three GMMG trials. Furthermore, she was the principle investigator in several national and international phase I-III clinical trials. She has contributed to more than 100 publications on multiple myeloma treatment and biology.